-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Squamous non-small cell lung cancer (sq NSCLC ) accounts for about 25-30% of non-small cell lung cancer (NSCLC).
Squamous non-small cell lung cancer (sq NSCLC ) accounts for about 25-30% of non-small cell lung cancer (NSCLC).
ORIENT-12 is an evaluation conducted in 42 research centers in my country, Daboshu® (sintilimab injection) or placebo combined with gemcitabine and platinum (GP) for advanced or recurrent squamous non-small cells A randomized, double-blind, phase III controlled clinical trial on the effectiveness and safety of the first-line treatment of lung cancer (Clinicaltrials.
ORIENT-12 is an evaluation conducted in 42 research centers in my country, Daboshu® (sintilimab injection) or placebo combined with gemcitabine and platinum (GP) for advanced or recurrent squamous non-small cells A randomized, double-blind, phase III controlled clinical trial on the effectiveness and safety of the first-line treatment of lung cancer (Clinicaltrials.
From September 25, 2018 to July 26, 2019, 543 patients were evaluated, of which 357 patients were randomly assigned to treat sintilimab+GP group (n=179) and placebo+GP group (n=178) ).
research summary
The median follow-up time was 12.
The median follow-up time was 12.
PFS
The median OS is immature.
The median OS is immature.
OS
Treatment-related adverse events (TEAE) of grade 3 and above in the two groups occurred in 86.
Treatment-related adverse events (TEAE) of grade 3 and above in the two groups occurred in 86.
Treatment-related adverse events
In summary, the study shows that sintilimab combined with gemcitabine/platinum can bring PFS benefits to gemcitabine/platinum in the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer.
In summary, the study shows that sintilimab combined with gemcitabine/platinum can bring PFS benefits to gemcitabine/platinum in the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer.
OS is immature, and the toxicity can be tolerated.
control.
This study shows that sintilimab combined with gemcitabine/platinum can bring PFS benefit to the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer with gemcitabine/platinum.
OS is immature, and the toxicity is tolerable and controllable.
This study shows that sintilimab combined with gemcitabine/platinum can bring PFS benefit to the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer with gemcitabine/platinum.
OS is immature, and the toxicity is tolerable and controllable.
Original source:
Original source:Zhou C, Wu L, Fan Y, et al.
Sintilimab plus platinum and gemcitabine as first-line treatment for advanced ormetastatic squamous non-small-cell lung cancer: results from a randomized, double-blind, phase 3 trial(ORIENT-12 ), Journal of Thoracic Oncology (2021), doi: https://doi.
org/10.
1016/j.
jtho.
2021.
04.
011.
Sintilimab plus platinum and gemcitabine as first-line treatment for advanced ormetastatic squamous non-small-cell lung cancer: results from a randomized, double-blind, phase 3 trial(ORIENT-12 ), Journal of Thoracic Oncology (2021), doi: https://doi.
org/10.
1016/j.
jtho.
2021.
04.
011.
Leave a message here
